PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17963432-0	2007	Megestrol acetate NCD oral suspension--Par Pharmaceutical: megestrol acetate nanocrystal dispersion oral suspension, PAR 100.2, PAR-100.2.	Megestrol Acetate	0-17	jumping translocation breakpoint	Homo sapiens	39-42	
17596111-0	2007	Megestrol acetate NCD oral suspension -- Par Pharmaceutical: megestrol acetate nanocrystal dispersion oral suspension, PAR 100.2, PAR-100.2.	Megestrol Acetate	0-17	jumping translocation breakpoint	Homo sapiens	41-44	
17596111-1	2007	Par Pharmaceutical has developed megestrol acetate (Megace ES) oral suspension for the treatment of anorexia, cachexia and a significant weight loss associated with AIDS.	Megestrol Acetate	33-50	jumping translocation breakpoint	Homo sapiens	0-3	
17596111-1	2007	Par Pharmaceutical has developed megestrol acetate (Megace ES) oral suspension for the treatment of anorexia, cachexia and a significant weight loss associated with AIDS.	Megestrol Acetate	52-61	jumping translocation breakpoint	Homo sapiens	0-3	
17596111-2	2007	Par Pharmaceutical used Elan Corporation"s NanoCrystal Dispersion (NCD) technology to develop an advanced, concentrated formulation of megestrol acetate with improved bioavailability, more rapid onset of action, more convenient dosing and a lower dosing regimen compared with the original marketed formulation of megestrol acetate oral suspension.	Megestrol Acetate	135-152	jumping translocation breakpoint	Homo sapiens	0-3	
17596111-2	2007	Par Pharmaceutical used Elan Corporation"s NanoCrystal Dispersion (NCD) technology to develop an advanced, concentrated formulation of megestrol acetate with improved bioavailability, more rapid onset of action, more convenient dosing and a lower dosing regimen compared with the original marketed formulation of megestrol acetate oral suspension.	Megestrol Acetate	313-330	jumping translocation breakpoint	Homo sapiens	0-3	
17596111-4	2007	The new megestrol acetate NCD formulation represents a line-extension of Par"s megestrol acetate oral suspension (800mg/20mL, Megace O/S) that has been marketed for anorexia, cachexia and AIDS-related weight loss since July 2001.	Megestrol Acetate	8-25	jumping translocation breakpoint	Homo sapiens	73-76	
17596111-10	2007	The NDA for the product was accepted for review by the agency in September 2004, following its submission in June of that year.Par Pharmaceutical commenced the first of two phase III clinical trials of megestrol acetate oral suspension (PAR 100.2) in cancer-induced anorexia in the first quarter of 2006.	Megestrol Acetate	202-219	jumping translocation breakpoint	Homo sapiens	127-130	
17596111-12	2007	The company intends to discuss future development options in this indication with the FDA.New formulations or dosage forms of megestrol acetate concentrated suspension are also in development; Par Pharmaceutical believes these may be available sometime after 2008.	Megestrol Acetate	126-143	jumping translocation breakpoint	Homo sapiens	193-196	
17596111-15	2007	The patent covers more than 30 additional claims in connection with Par Pharmaceutical"s novel formulation of megestrol acetate, and includes claims relating to the advanced formulation of megestrol acetate, specifically to the reduction of the food effect seen with previous formulations of megestrol acetate.	Megestrol Acetate	110-127	jumping translocation breakpoint	Homo sapiens	68-71	
17596111-21	2007	Both companies settled the lawsuit in July 2004 with Par granting a licence to Teva USA for a limited number of units and Par receiving royalties on Teva USA"s net sales of megestrol acetate oral suspension.	Megestrol Acetate	173-190	jumping translocation breakpoint	Homo sapiens	53-56	
17963432-1	2007	Par Pharmaceutical has developed megestrol acetate (Megace ES) oral suspension for the treatment of anorexia, cachexia and a significant weight loss associated with AIDS.	Megestrol Acetate	33-50	jumping translocation breakpoint	Homo sapiens	0-3	
17963432-1	2007	Par Pharmaceutical has developed megestrol acetate (Megace ES) oral suspension for the treatment of anorexia, cachexia and a significant weight loss associated with AIDS.	Megestrol Acetate	52-61	jumping translocation breakpoint	Homo sapiens	0-3	
17963432-2	2007	Par Pharmaceutical used Elan Corporation"s NanoCrystal Dispersion (NCD) technology to develop an advanced, concentrated formulation of megestrol acetate with improved bioavailability, more rapid onset of action, more convenient dosing and a lower dosing regimen compared with the original marketed formulation of megestrol acetate oral suspension.	Megestrol Acetate	135-152	jumping translocation breakpoint	Homo sapiens	0-3	
17963432-2	2007	Par Pharmaceutical used Elan Corporation"s NanoCrystal Dispersion (NCD) technology to develop an advanced, concentrated formulation of megestrol acetate with improved bioavailability, more rapid onset of action, more convenient dosing and a lower dosing regimen compared with the original marketed formulation of megestrol acetate oral suspension.	Megestrol Acetate	313-330	jumping translocation breakpoint	Homo sapiens	0-3	
17963432-4	2007	The new megestrol acetate NCD formulation represents a line-extension of Par"s megestrol acetate oral suspension (800mg/20mL, Megace O/S) that has been marketed for anorexia, cachexia and AIDS-related weight loss since July 2001.	Megestrol Acetate	8-25	jumping translocation breakpoint	Homo sapiens	73-76	
17963432-10	2007	The NDA for the product was accepted for review by the agency in September 2004, following its submission in June of that year.Par Pharmaceutical commenced the first of two phase III clinical trials of megestrol acetate oral suspension (PAR 100.2) in cancer-induced anorexia in the first quarter of 2006.	Megestrol Acetate	202-219	jumping translocation breakpoint	Homo sapiens	127-130	
17963432-12	2007	The company intends to discuss future development options in this indication with the FDA.New formulations or dosage forms of megestrol acetate concentrated suspension are also in development; Par Pharmaceutical believes these may be available sometime after 2008.	Megestrol Acetate	126-143	jumping translocation breakpoint	Homo sapiens	193-196	
17963432-15	2007	The patent covers more than 30 additional claims in connection with Par Pharmaceutical"s novel formulation of megestrol acetate, and includes claims relating to the advanced formulation of megestrol acetate, specifically to the reduction of the food effect seen with previous formulations of megestrol acetate.	Megestrol Acetate	110-127	jumping translocation breakpoint	Homo sapiens	68-71	
17963432-21	2007	Both companies settled the lawsuit in July 2004 with Par granting a licence to Teva USA for a limited number of units and Par receiving royalties on Teva USA"s net sales of megestrol acetate oral suspension.	Megestrol Acetate	173-190	jumping translocation breakpoint	Homo sapiens	53-56